AI drug development startup Pathos AI closes $237M investment
Pathos AI announced a Series E funding round of $237 million, valuing the company at $3 billion. Bristol Myers Squibb led the round with participation from returning investors including AstraZeneca, NEA, and General Atlantic. The startup focuses on developing cancer drugs using AI technology, representing significant interest from pharmaceutical majors in AI-driven drug development.
Key points
- Raises $237M Series E at $3B valuation
- Led by Bristol Myers Squibb with pharma and venture investors participating
- Focused on AI-enabled cancer drug development
Summary and key points written by AI from the headline and a short excerpt, so they can be incomplete or wrong. SiliconANGLE did the reporting; read the original for the full story.
Read the full story at SiliconANGLE
